Physician profile
Puneeth Iyengar
NPI 1205168887
$60,237.72
in general payments reported to CMS, 2019-2025
13 companies · $17K in 2025
The $17K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,562 · 2020: $6,515 · 2021: $2,519 · 2022: $8,658 · 2023: $11K · 2024: $13K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,700 · Honoraria: $3,980 · Travel and Lodging: $2,747 · Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,101.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,700.00 |
| Honoraria | $3,980.00 |
| Travel and Lodging | $2,747.02 |
| Food and Beverage | $2,455.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,717.32 | 2021-2025 | Tagrisso, Imfinzi, Onglyza |
| Astrazeneca Uk Limited | $8,758.70 | 2019-2024 | |
| Pfizer INC. | $8,754.99 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,750.00 | 2020-2022 | |
| Novocure INC. | $4,225.97 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Janssen Biotech, INC. | $1,977.40 | 2024 | Rybrevant |
| Ge Healthcare | $1,354.57 | 2022-2023 | |
| Siemens Medical Solutions USA, INC. | $264.82 | 2021-2022 | |
| Viewray Technologies INC | $198.24 | 2022 | |
| Tempus Ai, INC | $180.56 | 2024-2025 | Xt Cdx |
| Genentech, INC. | $38.48 | 2023 | Alecensa, Gavreto, Avastin |
| Genentech USA, INC. | $16.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneeth Iyengar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.